drugset
drugset / Trial / NCT07146217

Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection

NCT07146217 ↗

Phase 2 Not yet recruiting 30 enrolled Saptalis Pharmaceuticals LLC CBCC Global Research · collab
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, single-arm, pharmacokinetic and safety study of Likmez® in pediatric patients aged 12 months to \<4 years with anaerobic bacterial infection

Timeline

Start
2025-08
Primary completion
2026-07
Completion
2026-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Metronidazole Small molecule 7.5 mg/kg Oral

Indications

bacterial infectious disease